Cardiovascular Manifestation of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents

Suyanee Mansanguan, Prakaykaew Charunwatthana, Watcharapong Piyaphanee, Wilanee Dechkhajorn, Akkapon Poolcharoen, Chayasin Mansanguan, Suyanee Mansanguan, Prakaykaew Charunwatthana, Watcharapong Piyaphanee, Wilanee Dechkhajorn, Akkapon Poolcharoen, Chayasin Mansanguan

Abstract

This study focuses on cardiovascular manifestation, particularly myocarditis and pericarditis events, after BNT162b2 mRNA COVID-19 vaccine injection in Thai adolescents. This prospective cohort study enrolled students aged 13-18 years from two schools, who received the second dose of the BNT162b2 mRNA COVID-19 vaccine. Data including demographics, symptoms, vital signs, ECG, echocardiography, and cardiac enzymes were collected at baseline, Day 3, Day 7, and Day 14 (optional) using case record forms. We enrolled 314 participants; of these, 13 participants were lost to follow-up, leaving 301 participants for analysis. The most common cardiovascular signs and symptoms were tachycardia (7.64%), shortness of breath (6.64%), palpitation (4.32%), chest pain (4.32%), and hypertension (3.99%). One participant could have more than one sign and/or symptom. Seven participants (2.33%) exhibited at least one elevated cardiac biomarker or positive lab assessments. Cardiovascular manifestations were found in 29.24% of patients, ranging from tachycardia or palpitation to myopericarditis. Myopericarditis was confirmed in one patient after vaccination. Two patients had suspected pericarditis and four patients had suspected subclinical myocarditis. In conclusion, Cardiovascular manifestation in adolescents after BNT162b2 mRNA COVID-19 vaccination included tachycardia, palpitation, and myopericarditis. The clinical presentation of myopericarditis after vaccination was usually mild and temporary, with all cases fully recovering within 14 days. Hence, adolescents receiving mRNA vaccines should be monitored for cardiovascular side effects. Clinical Trial Registration: NCT05288231.

Keywords: BNT162b2 mRNA COVID-19 vaccine; COVID-19 vaccine; Thailand; adolescents; cardiovascular manifestation; myocarditis.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Study flow chart. CK-MB, creatine kinase-myocardial band; ECG, electrocardiography; Trop-T, troponin-T.
Figure 2
Figure 2
(A–F) cMRI illustrating LGE in a patient with subacute myopericarditis at the time of diagnosis (A–C) and 5 months post-diagnosis (D–F). cMRI, cardiac magnetic resonance imaging; LGE, late gadolinium enhancement.

References

    1. Skowronski D.M., De Serres G. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 2021;384:1576–1577.
    1. Walsh E.E., Frenck R.W., Jr., Falsey A.R., Kitchin N., Absalon J., Gurtman A., Lockhart S., Neuzil K., Mulligan M.J., Bailey R., et al. Safety and Immunogenicity of two RNA-based COVID-19 Vaccine Candidates. N. Engl. J. Med. 2020;383:2439–2450. doi: 10.1056/NEJMoa2027906.
    1. Oliver S.E., Gargano J.W., Marin M., Wallace M., Curran K.G., Chamberland M., McClung N., Campos-Outcalt D., Morgan R.L., Mbaeyi S., et al. The Advisory Committee on Immunization Practice’s Interim Recommendation for use Pfizer-BioNTech COVID-19 vaccine–United States, December 2020. Morb. Mortal. Wkly. Rep. 2020;69:1922–1924. doi: 10.15585/mmwr.mm6950e2.
    1. Faix D.J., Gordon D.M., Perry L.N., Raymond-Loher I., Tati N., Lin G., DiPietro G., Selmani A., Decker M.D. Prospective safety surveillance study of ACAM2000 smallpox vaccine in deploying military personnel. Vaccine. 2020;38:7323–7330. doi: 10.1016/j.vaccine.2020.09.037.
    1. Muthukumar A., Narasimhan M., Li Q.-Z., Mahimainathan L., Hitto I., Fuda F., Batra K., Jiang X., Zhu C., Schoggins J., et al. In-Depth Evaluation of a Case of Presumed Myocarditis After the Second Dose of COVID-19 mRNA Vaccine. Circulation. 2021;144:487–498. doi: 10.1161/CIRCULATIONAHA.121.056038.
    1. Tschöpe C., Ammirati E., Bozkurt B., Caforio A.L.P., Cooper L.T., Felix S.B., Hare J.M., Heidecker B., Heymans S., Hübner N., et al. Myocarditis and inflammatory cardiomyopathy: Current evidence and future directions. Nat. Rev. Cardiol. 2021;18:169–193. doi: 10.1038/s41569-020-00435-x.
    1. Fairweather D., Cooper L.T., Blauwet L.A. Sex and Gender Differences in Myocarditis and Dilated Cardiomyopathy. Curr. Probl. Cardiol. 2013;38:7–46. doi: 10.1016/j.cpcardiol.2012.07.003.
    1. Witberg G., Barda N., Hoss S., Richter I., Wiessman M., Aviv Y., Grinberg T., Auster O., Dagan N., Balicer R.D., et al. Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. N. Engl. J. Med. 2021;385:2132–2139. doi: 10.1056/NEJMoa2110737.
    1. Mevorach D., Anis E., Cedar N., Bromberg M., Haas E.J., Nadir E., Olsha-Castell S., Arad D., Hasin T., Levi N., et al. Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. N. Engl. J. Med. 2021;385:2140–2149. doi: 10.1056/NEJMoa2109730.
    1. Gargano J.W., Wallace M., Hadler S.C., Langley G., Su J.R., Oster M.E., Broder K.R., Gee J., Weintraub E., Shimabukuro T., et al. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices—United States, June 2021. MMWR. Morb. Mortal. Wkly. Rep. 2021;70:977–982. doi: 10.15585/mmwr.mm7027e2.
    1. Caforio A.L., Pankuweit S., Arbustini E., Basso C., Gimeno-Blanes J., Felix S.B., Fu M., Heliö T., Heymans S., Jahns R., et al. European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur. Heart J. 2013;34:2636–2648.
    1. Su J.R., McNeil M.M., Welsh K.J., Marquez P.L., Ng C., Yan M., Cano M.V. Myopericarditis after vaccination, Vaccine Adverse Event Reporting System (VAERS), 1990–2018. Vaccine. 2021;39:839–845. doi: 10.1016/j.vaccine.2020.12.046.
    1. Shimabukuro T.T., Nguyen M., Martin D., DeStefano F. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS) Vaccine. 2015;33:4398–4405. doi: 10.1016/j.vaccine.2015.07.035.
    1. Guo T., Fan Y., Chen M., Wu X., Zhang L., He T., Wang H., Wan J., Wang X., Lu Z. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) JAMA Cardiol. 2019;5:811–818. doi: 10.1001/jamacardio.2020.1017.
    1. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practice (ACIP). Coronavirus Disease 2019 (COVID-19) Vaccines. [(accessed on 23 January 2022)]; Available online: .
    1. Kuntz J., Crane B., Weinmann S., Naleway A.L. Myocarditis and pericarditis are rare following live viral vaccinations in adults. Vaccine. 2018;36:1524–1527. doi: 10.1016/j.vaccine.2018.02.030.
    1. García J.B., Ortega P.P., Fernández J.A.B., León A.C., Burgos L.R., Dorta E.C. Acute myocarditis after administration of the BNT162b2 vaccine against COVID-19. Rev. Esp. Cardiol. 2021;74:812–814. doi: 10.1016/j.recesp.2021.03.009.
    1. Bozkurt B., Kamat I., Hotez P.J. Myocarditis With COVID-19 mRNA Vaccines. Circulation. 2021;144:471–484. doi: 10.1161/CIRCULATIONAHA.121.056135.
    1. Kaur R.J., Dutta S., Charan J., Bhardwaj P., Tandon A., Yadav D., Islam S., Haque M. Cardiovascular Adverse Events Reported from COVID-19 Vaccines: A Study Based on WHO Database. Int. J. Gen. Med. 2021;14:3909–3927. doi: 10.2147/IJGM.S324349.
    1. Pardi N., Hogan M.J., Porter F.W., Weissman D. mRNA vaccines-a new era in vaccinology. Nat. Rev. Drug Discov. 2018;17:261–279. doi: 10.1038/nrd.2017.243.
    1. US Food and Drug Administration . Coronavirus (COVID-19) Update: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Adolescents in Another Importance Action in Flight Against Pandemic. US Food and Drug Administration; Silver Spring, MD, USA: 2021.
    1. Montgomery J., Ryan M., Engler R., Hoffman D., McClenathan B., Collins L., Loran D., Hrncir D., Herring K., Platzer M., et al. Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. JAMA Cardiol. 2021;6:1202–1206. doi: 10.1001/jamacardio.2021.2833.
    1. Mouch S.A., Roguin A., Hellou E., Ishai A., Shoshan U., Mahamid L., Zoabi M., Aisman M., Goldschmid N., Yanay N.B. Myocarditis following COVID-19 mRNA vaccination. Vaccine. 2021;39:3790–3793. doi: 10.1016/j.vaccine.2021.05.087.
    1. Power J.R., Keyt L.K., Adler E.D. Myocarditis following COVID-19 vaccination: Incidence, mechanisms, and clinical considerations. Expert Rev. Cardiovasc. Ther. 2022;20:241–251. doi: 10.1080/14779072.2022.2066522.
    1. Hajjo R., Sabbah D.A., Bardaweel S.K., Tropsha A. Shedding the Light on Post-Vaccine Myocarditis and Pericarditis in COVID-19 and Non-COVID-19 Vaccine Recipients. Vaccines. 2021;9:1186. doi: 10.3390/vaccines9101186.
    1. Wolff J.A., Malone R.W., Williams P., Chong W., Acsadi G., Jani A., Felgner P.L. Direct gene transfer into mouse muscle in vivo. Science. 1990;247 Pt 1:1465–1468. doi: 10.1126/science.1690918.
    1. Ahin U., Karikó K., Türeci Ö. mRNA-based therapeutics—developing a new class of drugs. Nat. Rev. Drug Discov. 2014;13:759–780. doi: 10.1038/nrd4278.
    1. Vora S.M., Lieberman J., Wu H. Inflammasome activation at the crux of severe COVID-19. Nat. Rev. Immunol. 2021;21:694–703. doi: 10.1038/s41577-021-00588-x.
    1. Chilamahuri R., Agarwal S. COVID-19: Characteristics and Therapeutics. Cells. 2021;10:206. doi: 10.3390/cells10020206.
    1. Aikawa T., Takagi H., Ishikawa K., Kuno T. Myocardial injury characterized by elevated cardiac troponin and in-hospital mortality of COVID-19: An insight from a meta-analysis. J. Med. Virol. 2021;93:51–55. doi: 10.1002/jmv.26108.
    1. Maiese A., Frati P., Del Duca F., Santoro P., Manetti A.C., La Russa R., Di Paolo M., Turillazzi E., Fineschi V. Myocardial Pathology in COVID-19-Associated Cardiac Injury: A Systematic Review. Diagnostics. 2021;11:1647. doi: 10.3390/diagnostics11091647.
    1. Tano E., San Martin S., Girgis S., Martinez-Fernandez Y., Sanchez Vegas C. Perimyocarditis in adolescents after Pfizer-BioNTech COVID-19 vaccine. J. Pediatr. Infect. Dis. Soc. 2021;10:962–966. doi: 10.1093/jpids/piab060.
    1. Marshall M., Ferguson I.D., Lewis P., Jaggi P., Gagliardo C., Collins J.S., Shaughnessy R., Caron R., Fuss C., Corbin K.J.E., et al. Symptomatic acute myocarditis in 7 adolescents after Pfizer-BioNTech COVID-19 vaccination. Pediatrics. 2021;148:e2021052478. doi: 10.1542/peds.2021-052478.
    1. Ashor A.W., Lara J., Mathers J.C., Siervo M. Effect of vitamin C on endothelial function in health and disease: A systematic review and meta-analysis of randomized controlled trials. Athersclerosis. 2014;235:9–20. doi: 10.1016/j.atherosclerosis.2014.04.004.
    1. Berretta M., Quagliariello V., Maurea N., Di Francia R., Sharifi S., Facchini G., Rinaldi L., Piezzo M., Manuela C., Nunnari G., et al. Multiple Effects of Ascorbic Acid against Chronic Diseases: Updated Evidence from Preclinical and Clinical Studies. Antioxidants. 2020;9:1182. doi: 10.3390/antiox9121182.
    1. Hsiao J.F., Koshino Y., Bonnichsen C.R., Yu Y., Miller FAJr Pellikka P.A., Cooper L.T., Jr. Villarraga HR. Speckle tracking echocardiography in acute myocarditis. Int. J. Cardiovasc. Imaging. 2013;29:275–284. doi: 10.1007/s10554-012-0085-6.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel